Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
Globe Newswire•04/11/2026•07:30 ET
0
Key Highlights
- ➤Atebimetinib plus mGnP achieved 17.3 months median overall survival in first-line pancreatic cancer Phase 2.
- ➤Immuneering will present biomarker-enriched atebimetinib combinations for pancreatic ductal adenocarcinoma at a Poster Spotlight session.
- ➤New preclinical data supports atebimetinib chemotherapy combinations in anaplastic thyroid cancer.
- ➤Atebimetinib is being evaluated in the Phase 3 MAPKeeper 301 first-line pancreatic cancer trial.
- Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib + mGnP, as presented in June at ASCO -
- Poster spotlight session will highlight broad set of additional opportunities to combine atebimetinib with agents targeting multiple oncogenic pathways in pancreatic cancer -
Get started
Create a free account to read the full story.